EFTR

eFFECTOR Therapeutics, Inc. [EFTR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

EFTR Stock Summary

In the News

EFTR Financial details

Company Rating
-
Market Cap
7.67M
Income
-35.81M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-0.75
Forward P/E
-
PEG
-0.06
P/S
-
P/B
-6.89
P/C
-
P/FCF
-0.93
Quick Ratio
0.75
Current Ratio
0.82
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-17.11
EPS next Y
-
EPS next Q
-
EPS this Y
108.54%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
1.79%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-180%
ROE
6281%
ROC
9.98%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.03-37.0
52W High
-100%
52W Low
-99.99%
RSI
47.95
Rel Volume
-
Avg Volume
374.1K
Volume
1
Perf Week
0%
Perf Month
0%
Perf Quarter
0%
Perf Half Y
0%
-
-
-
-
Beta
0.523
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0002
Change
0%

Something similar

Top by Market Cap
VTI
BRYN.DE
FXAIX
TSLA
GOOG
Same Sector
CLVS
OTRK
ORINY
CJJD
INAB
Same Price Range
LRDG
LTGJ
XSNX
PVNNF
SANT
Similar Market Cap
BTRYF
MEMX
8427.HK
GTHP
BOXL

Company Profile

Healthcare Biotechnology
  • Volume Average 374.1K
  • Market Capitalization 7.67M
  • Employee 14
  • CEO Dr. Stephen T. Worland Ph.D.
  • Headquarters Solana Beach,CA,US
  • IPO Date 2021-03-01
  • Website https://effector.com

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.